Develops antibody-based immunotherapies for cancer treatment, utilizing a proprietary platform to enhance efficacy and safety.
Adagene Inc. is a dynamic clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the research, development, and production of monoclonal antibody drugs targeted at various cancers. The company's robust pipeline includes innovative product candidates designed to address significant unmet medical needs across a spectrum of cancer types.
Among Adagene's leading candidates is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody (mAb) currently undergoing Phase 1b/2 clinical trials for the treatment of advanced solid tumors and non-Hodgkin's lymphoma. Additionally, ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, a human ligand-blocking anti-CTLA-4 mAb, are both in Phase 1 clinical trials for the treatment of advanced/metastatic solid tumors, showcasing Adagene's commitment to advancing novel therapies.
Founded in 2011, Adagene leverages cutting-edge research platforms and strategic collaborations to drive its innovative pipeline forward. The company also offers promising candidates like ADG104, an anti-PD-L1 mAb in Phase 2 clinical development, and ADG125, a novel anti-CSF-1R mAb in Phase 1 clinical trials. With a focus on advancing groundbreaking treatments through rigorous scientific exploration, Adagene aims to redefine cancer care and improve outcomes for patients worldwide.